Enzyme News and Research

RSS

Researchers identify immune protein linked to rare neurodegenerative disease

UT Southwestern researchers have identified an immune protein tied to the rare neurodegenerative condition known as Niemann-Pick disease type C.

21 Jul 2021

Existing drug may be effective in treating COVID-19

A new University of Chicago study has found that the drug masitinib may be effective in treating COVID-19.

21 Jul 2021

Intestinal organoids demonstrate variability in SARS-CoV-2 susceptibility

Three-dimensional organoid structures grown in the lab allow deeper, almost in situ investigation of a biological system, without the use of living animals. In a paper recently uploaded to the preprint server bioRxiv*, organoids generated from human specimens are utilized to investigate the way in which SARS-CoV-2 interacts with the numerous cells of the intestinal epithelium, finding great heterogeneity in the susceptibility of the organoids and the cells within to infection.

21 Jul 2021

Potent nasal vaccine protects non-human primates from SARS-CoV-2

A team of US-based scientists has recently demonstrated the efficacy of a live attenuated, recombinant coronavirus disease 2019 (COVID-19) vaccine candidate currently under phase I clinical trial as a single-dose intranasal vaccine.

20 Jul 2021

Structural changes in receptor-binding interface may induce immune fitness of SARS-CoV-2 delta variant

Florida International University researchers have investigated the mutation-induced structural changes in the delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could contribute to its immune evasion abilities.

20 Jul 2021

Next-generation COVID-19 vaccine provides robust immunity against SARS-CoV-2 in mice

Researchers in Canada have developed an adenoviral vector-based vaccine against coronavirus disease 2019 (COVID-19) that induced robust immune protection against the ancestral strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in mice.

20 Jul 2021

Yeast expressed, RBD-based vaccine provides robust immune responses against SARS-CoV-2

The ongoing coronavirus disease (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused over 190 million cases worldwide. Of these, over 4 million have died due to the infection.

20 Jul 2021

Study proves effectiveness of Artemisia annua against SARS-CoV-2 in vitro

A multinational research group has been the first to show the excellent activity of artemisinin-based treatment against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in human cell lines – including a specific type of lung cells. Their findings were recently published in the journal Scientific Reports.

19 Jul 2021

Neutralizing antibodies persist against SARS-CoV-2 at least a year after infection

Researchers in Finland have conducted a study showing that the neutralizing bodies generated following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – generally persist for at least a year.

19 Jul 2021

A novel method developed for producing new antibiotics to combat resistant bacteria

Researchers at Children's Hospital of Philadelphia have developed a novel method for producing new antibiotics to combat resistant bacteria.

19 Jul 2021

Dysbiosis in gut microbiota may cause severe secondary infection in COVID-19 patients

An interesting study led by scientists in the U.S. has recently revealed that the microbial community in the gut is directly affected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and that virus-mediated gut microbiome dysbiosis may cause severe secondary infections in coronavirus disease 2019 (COVID-19) patients. The study is currently available on the bioRxiv* preprint server.

19 Jul 2021

Stronger and longer SARS-CoV-2 RBD-ACE2 binding associated with glycans in new study

A new study has been published on the bioRxiv* preprint server, which focuses on the mechanism behind the binding of SARS-CoV-2 with the host receptor, using a molecular dynamics approach. The authors of this study aim to highlight the role of glycans in initiating the interaction between S and ACE2.

19 Jul 2021

Preventing lethal blood clots

In our latest interview, we spoke to Professor Robert Ariëns from the University of Leeds about his latest research into blood clots and how they can be prevented.

19 Jul 2021

An assay capable of detecting SARS-CoV-2 antibodies in breast milk and other samples

In a recent study by US researchers (currently available on the medRxiv* preprint server), a specific immunoassay based on the spike glycoprotein’s receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is not only well suited for the detection of antibody response after infection and vaccination but may also represent a method of choice when conducting seroepidemiological studies.

19 Jul 2021

SARS-CoV-2 B.1.617 mutations L452 and E484Q do not work together to evade antibodies

A short report recently published in the Journal of Infectious Diseases demonstrates how spike mutations L452R and E484Q found in the variant B.1.617.1 of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) each confer modestly diminished sensitivity to Pfizer-BioNTech (BNT162b2) mRNA vaccine-elicited antibodies – with combined mutations having a similar impact as either one of them alone.

19 Jul 2021

Enzyme News and Research

Researchers identify immune protein linked to rare neurodegenerative disease

Existing drug may be effective in treating COVID-19

Intestinal organoids demonstrate variability in SARS-CoV-2 susceptibility

Potent nasal vaccine protects non-human primates from SARS-CoV-2

Structural changes in receptor-binding interface may induce immune fitness of SARS-CoV-2 delta variant

Next-generation COVID-19 vaccine provides robust immunity against SARS-CoV-2 in mice

Yeast expressed, RBD-based vaccine provides robust immune responses against SARS-CoV-2

Study proves effectiveness of Artemisia annua against SARS-CoV-2 in vitro

Neutralizing antibodies persist against SARS-CoV-2 at least a year after infection

A novel method developed for producing new antibiotics to combat resistant bacteria

Dysbiosis in gut microbiota may cause severe secondary infection in COVID-19 patients

Stronger and longer SARS-CoV-2 RBD-ACE2 binding associated with glycans in new study

Preventing lethal blood clots

An assay capable of detecting SARS-CoV-2 antibodies in breast milk and other samples

SARS-CoV-2 B.1.617 mutations L452 and E484Q do not work together to evade antibodies

Evaluation of a synthetic DNA SARS-CoV-2 vaccine INO-4800 using a nonhuman primate model

A drug candidate to prevent adverse reactions due to COVID-19 infection or vaccines

Central amygdala micro-circuits play active role in regulation of fear responses

Research shows a direct link between SUV39H2 gene and autism spectrum disorders

Gene therapy delivered into the brain may be safe, effective in treating rare neurological disorder

Biochemistry eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo